NKTR vs PATH · rev $98.4M vs P/E 19, rev $1.61B
Nektar Therapeutics (NKTR) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported NKTR revenue for 2024-12-31 was $98.4M. Net income was -$119.0M. Revenue was up 9.2% from 2023-12-31 to 2024-12-31. NKTR currently screens at market cap $307.2M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
NKTR currently screens at market cap $307.2M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the NKTR and PATH stock pages for the full models.
Not investment advice.